This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published on July 11
The FDA's approval of safer dosing for Alzheimer's drugs has created a domino effect of positive developments across the entire treatment landscape. This regulatory win signals major commercial potential for all companies in this space.
With over 6 million Americans living with Alzheimer's and safer treatments now emerging, these companies are targeting an enormous and largely underserved market. Safer treatments mean wider adoption and potentially billions in revenue.
This group includes not just drug developers but also the diagnostic, imaging, and delivery technology companies that enable successful treatment. As the main therapies grow, so do the supporting technologies that make them possible.
The FDA's approval of a safer dosing protocol for Eli Lilly's Alzheimer's drug marks a pivotal moment for neurodegenerative treatments. This breakthrough not only improves a single therapy but signals a broader shift toward making powerful treatments more accessible, creating investment opportunities across the entire treatment ecosystem.
This group includes diverse companies from major pharmaceutical developers to innovative biotechs and specialized support firms. While some directly manufacture treatments, others provide essential services like brain imaging, diagnostics, and clinical trial management that enable the broader Alzheimer's treatment revolution.
These companies were handpicked by professional analysts to capture the full spectrum of the safer Alzheimer's treatment breakthrough. The selection includes established leaders with approved therapies, promising clinical-stage biotechs, and specialized firms whose technologies are critical to the successful deployment of these treatments.
Market capitalisation breakdown for the 'Safer Alzheimer's Treatments' basket and investor key takeaways.
LLY: $756.76B
BIIB: $21.44B
AVXL: $803.11M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+5
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
BHP Group recently posted a massive earnings beat driven by record copper profitability, allowing the miner to raise its dividend to a four-year high. This performance highlights a structural shift toward electrification metals, creating opportunities for industrial equipment suppliers and competing copper producers.
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly & Co
LLY
Current Price
$1,279.99
As the manufacturer of Kisunla, Eli Lilly is the primary beneficiary of the FDA's approval for a safer dosing schedule, which is expected to increase ...
As the manufacturer of Kisunla, Eli Lilly is the primary beneficiary of the FDA's approval for a safer dosing schedule, which is expected to increase physician adoption and boost sales.
BIOGEN INC
BIIB
Current Price
$220.24
A key competitor with its Alzheimer's drug Leqembi; Lilly's improved safety profile intensifies competition but also validates and expands the overall...
A key competitor with its Alzheimer's drug Leqembi; Lilly's improved safety profile intensifies competition but also validates and expands the overall market for anti-amyloid therapies.
ANAVEX LIFE SCIENCES CORPORATION
AVXL
Current Price
$3.34
This clinical-stage company is developing treatments for Alzheimer's and benefits from increased investor interest and positive sentiment flowing into...
This clinical-stage company is developing treatments for Alzheimer's and benefits from increased investor interest and positive sentiment flowing into the entire neurodegenerative disease sector.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+199.15%
On average, analysts expect assets in this group to grow 199.15% over the next year.
13 of 15 assets in this group are rated Buy by professional analysts.
